We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

62 hedge funds and large institutions have $73.7M invested in Ovid Therapeutics in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

480% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 5

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

177% more capital invested

Capital invested by funds: $26.6M → $73.7M (+$47.1M)

63% more funds holding

Funds holding: 38 → 62 (+24)

15.93% more ownership

Funds ownership: 21.21% → 37.15% (+16%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
62
Holders Change
+24
Holders Change %
+63.16%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
22
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$9.12M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.58M
3
Axa
Axa
France
+$2.74M
4
Citigroup
Citigroup
New York
+$1.58M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$5.01M
2
Marshall Wace
Marshall Wace
United Kingdom
-$59K
3
MWNA
Marshall Wace North America
New York
-$41K
4
WG
Winton Group
United Kingdom
-$34K
5
Northern Trust
Northern Trust
Illinois
-$24.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
First Manhattan
51
First Manhattan
New York
$74K – – –
Commonwealth Equity Services
52
Commonwealth Equity Services
Massachusetts
$74K +$1.58K +500 +3%
AGM
53
Alpine Global Management
New York
$69K +$52.1K +16,509 New
Creative Planning
54
Creative Planning
Kansas
$64K +$1.9K +600 +4%
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
$28K +$10.5K +3,314 +99%
OSAM
56
O'Shaughnessy Asset Management
Connecticut
$21K +$15.7K +4,966 New
UBS Group
57
UBS Group
Switzerland
$17K +$12.6K +3,978 New
LWM
58
Lionsbridge Wealth Management
Florida
$2K +$2.37K +750 New
LTFS
59
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Federated Hermes
60
Federated Hermes
Pennsylvania
$1K +$1.01K +320 New
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$290 -$4.68K -1,481 -95%
Marshall Wace
62
Marshall Wace
United Kingdom
– -$59K -18,060 Closed
MWNA
63
Marshall Wace North America
New York
– -$41K -12,735 Closed
WG
64
Winton Group
United Kingdom
– -$34K -10,388 Closed
Victory Capital Management
65
Victory Capital Management
Texas
– -$15K -4,694 Closed
Bank of America
66
Bank of America
North Carolina
– -$10K -3,007 Closed
PHK
67
Point72 Hong Kong
Hong Kong
– +$272 +86 New
1 2
3

OVID Hedge Fund Activity: Q4 2019 in Review

62 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2019, worth a combined $73.7M — up 177% from $26.6M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new OVID positions and 5 closed out — a net gain of 24 holders — while 22 added to existing stakes and 5 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $9.12M. The largest seller was BVF Inc, cutting an estimated $5.01M.

  • 62 institutional investors held Ovid Therapeutics (OVID) as of Q4 2019, up from 38 in Q3 2019.
  • Funds reported $73.7M of Ovid Therapeutics stock for Q4 2019, up 177% quarter-over-quarter.
  • 29 funds opened new Ovid Therapeutics positions in Q4 2019 and 5 closed out, a net change of +24 holders.
  • The largest Ovid Therapeutics buyer in Q4 2019 was Consonance Capital Management, an estimated $9.12M added.
  • The largest Ovid Therapeutics seller in Q4 2019 was BVF Inc, an estimated $5.01M sold.

Based on aggregated 13F filings for Q4 2019.